Phase 1Completed
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
- Sponsor
- Cogent Biosciences, Inc. (Industry)
- Enrollment
- 34 enrolled
- Conditions
- Lymphoma
- Interventions
- ACTR087; rituximab
- Ages
- adults, older adults
- Registry
- NCT02776813
Full record on ClinicalTrials.gov
From the registry
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
Primary outcomes
- Safety as assessed by dose limiting toxicities (DLTs)
- Safety as assessed by determination of the maximum tolerated dose (MTD)
- Safety as assessed by determination of the recommended phase 2 dose (RP2D)
- Safety as assessed by and adverse events, laboratory assessments and physical examinations
History
Last registry update
Primary completion
Started
Registered